Evidence map›Paper›PMID 40253507›Full record

ArticleHuman cell2025

Hyaluronic acid-modified milk exosomes carrying ZNF516 inhibit ABCC5 and contribute to pemetrexed sensitivity in lung adenocarcinoma.

Hui Li, Yanyan Sun, Jue Wang, Zhiwu Wang, Lan Wu, Jie Lei, Ying Gao

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Li *Department of Internal Medicine Oncology, Inner Mongolia Autonomous Region People's Hospital, No. 20, Zhaowuda Road, Saihan District, Hohhot, 010017, Inner Mongolia Autonomous Region, People's Republic of China. lihui322222@163.com.
Yanyan Sun *Department of Internal Medicine Oncology, Inner Mongolia Autonomous Region People's Hospital, No. 20, Zhaowuda Road, Saihan District, Hohhot, 010017, Inner Mongolia Autonomous Region, People's Republic of China.
Jue WangDepartment of Internal Medicine Oncology, Inner Mongolia Autonomous Region People's Hospital, No. 20, Zhaowuda Road, Saihan District, Hohhot, 010017, Inner Mongolia Autonomous Region, People's Republic of China.
Zhiwu WangDepartment of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, 063001, Hebei, People's Republic of China.
Lan WuDepartment of Oncology, Clinical Medical College, Inner Mongolia Medical University, Hohhot, 010110, Inner Mongolia Autonomous Region, People's Republic of China.
Jie LeiDepartment of Oncology, Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, 014040, Inner Mongolia Autonomous Region, People's Republic of China.
Ying GaoDepartment of Oncology, Clinical Medical College, Inner Mongolia Medical University, Hohhot, 010110, Inner Mongolia Autonomous Region, People's Republic of China.

Funding

Natural Science Foundation Project of Inner Mongolia Autonomous Region (Joint Fund Project) (2023) 2023LHMS08006
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Milk-derived exosomes (mEXOs) have critical roles in cancer treatment. This paper explores the effects of hyaluronic acid (HA)-modified mEXOs (HA-mEXOs) in LUAD. HA-mEXOs were isolated and prepared, and PMX-resistant cells were developed. CCK-8, colony formation, Transwell, flow apoptosis, xenograft tumor assay, immunohistochemistry, and TUNEL experiments were conducted to explore the impact of mEXOs and HA-mEXOs on malignant behaviors and PMX sensitivity. The role of ZNF516 and ABCC5 on malignant behaviors and PMX sensitivity was investigated by shRNA lentiviral infection. HA modification increased the uptake and affinity of LUAD cells for mEXOs. mEXOs induced PMX-resistant LUAD cell sensitivity and inhibited their malignant behaviors. mEXOs enhanced PMX sensitivity and inhibited tumor growth. HA-mEXOs had superior effects to mEXOs. ZNF516 was lowered in LUAD-resistant cells and upregulated by mEXOs. ZNF516 bound to the ABCC5 promoter and repressed its transcriptional activation. The combined knockdown of ZNF516 reversed the antitumor benefits of mEXOs. HA-mEXOs-carrying ZNF516 enhance ZNF516 levels in LUAD/PMX cells and repress ABCC5, which in turn induces cell sensitivity to PMX and inhibits LUAD progression.

Indexed as

Adenocarcinoma of LungATP-Binding Cassette, Sub-Family C ProteinsDrug Resistance, NeoplasmExosomesHyaluronic AcidLung NeoplasmsMilkPemetrexedAnimalsAntineoplastic AgentsCell Line, TumorHumansABCC5 protein, humanAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsHyaluronic AcidPemetrexedABCC5Hyaluronic acidLung adenocarcinomaMilk-derived exosomesPemetrexed resistanceZNF516

Identifiers

PMID40253507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.